1. Home
  2. TNON vs NEUP Comparison

TNON vs NEUP Comparison

Compare TNON & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenon Medical Inc.

TNON

Tenon Medical Inc.

HOLD

Current Price

$1.06

Market Cap

12.8M

Sector

Health Care

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.80

Market Cap

10.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNON
NEUP
Founded
2012
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8M
10.3M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
TNON
NEUP
Price
$1.06
$3.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$3.00
$21.00
AVG Volume (30 Days)
73.3K
83.6K
Earning Date
11-13-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,233,000.00
$15,649,448.00
Revenue This Year
$19.56
N/A
Revenue Next Year
$71.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.85
$2.90
52 Week High
$5.85
$21.40

Technical Indicators

Market Signals
Indicator
TNON
NEUP
Relative Strength Index (RSI) 42.23 35.97
Support Level $1.06 $3.70
Resistance Level $1.13 $4.15
Average True Range (ATR) 0.04 0.24
MACD -0.00 0.10
Stochastic Oscillator 12.00 9.47

Price Performance

Historical Comparison
TNON
NEUP

About TNON Tenon Medical Inc.

Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: